Skip To Main Content
Sara Talpos on Muck Rack

Sara Talpos

Verified
Michigan
As seen in: UNDARK, The Guardian, The Independent (UK), TIME, The Atlantic, Ars Technica, Digg, Quartz, Slate, Firstpost, Flipboard and
Reporter and editor @undarkmag / Occasional freelance writing / Former lecturer @UM_English / Signal: saratalpos.64
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sara

Contact Sara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Interview: How Tragedy Changed the FDA

|
By Sara Talpos Verified
| UNDARK Verified
For decades, the U.S. Food and Drug Administration has served as a gatekeeper, tasked with preventing dangerous, ineffective, and under-studied pharmaceuticals from being placed on the market. If you take Wegovy to help treat obesity, Lipitor to manage high cholesterol, or Xanax to quell anxiety, you’re taking a medication that the agency has decided provides more benefits, on net, than harms. Where does its authority come from — and why was it granted? Mikkael A.
Open in Who Shared Issue with article?

Why Some Scientists Are Worried About the Peptide Boom

|
By Sara Talpos Verified
| MedShadow Foundation Blog Verified
FACT CHECKED For more than two decades, chemist Joshua Kritzer has studied peptides: short chains of amino acids that, when produced by the body, help cells communicate with each other. In his laboratory at Tufts University, Kritzer designs and tests peptides with the potential to treat diseases such as Alzheimer’s and cancer.
Open in Who Shared Issue with article?

Interview: California Lawmaker Calls for a Peptide Working Group

|
By Sara Talpos Verified
| UNDARK Verified
Should Americans have access to therapies that have not been fully vetted? Next month, an advisory committee to the U.S. Food and Drug Administration will weigh the question in the context of seven peptides marketed for benefits such as weight loss, tissue repair, and longevity. These particular peptides have not passed through the rigorous human testing required for drug approval.
Open in Who Shared Issue with article?
See all 131 licensed articles (140 Total)